ROS1 Laboratory Testing and Reporting Highlights - On Demand Webinar 3

Course overview

This on-demand case-based webinar is the last of a three-part series on ROS1 being released in 2017. The focus for this webinar is to highlight various clinical and technical considerations for the detection of ROS1. The activity offers 1 CME, CMLE, or SAMs CME credit. New therapies based on molecular biomarkers signify promising advances for those patients with NSCLC who have not responded to traditional chemotherapy treatment protocols. One such advance is the identification of therapeutic agents that target the ROS1 gene rearrangement. National Cancer Center Network (NCCN) 2015 Guidelines recommend ROS1 testing for targeted therapies in all appropriate patients with advanced lung cancer. In addition, the advent of targeted therapies has increased the awareness of the laboratory team’s crucial role in the management of lung cancer, and the direct impact testing, interpretation, and diagnosis of biomarkers has on patient therapies. However, pathologists and laboratory professionals must communicate effectively with their colleagues to ensure the accurate interpretation and management of ROS1 rearrangements in NSCLC. Clinical teams also lack clarity on the role of pathological testing in guiding selection of optimal treatment regimens. Clear communication and reporting of ROS1 results between the laboratory and the oncologist is necessary to ensure proper treatment. In this webinar, participants will learn the highlights of various the clinical-pathologic features of ROS1 rearranged lung cancers, an example of an algorithm for predictive biomarker testing in place in one institution, principles of ROS1 in Immunohistochemistry, and alternative approaches to detecting infusions from NGS data. Learning Objectives: • Identify optimal processes and procedures in performing ROS1 testing on patient specimens in accordance with CLIA regulations • Identify the pros and cons of ROS1 testing methodologies The American Society for Clinical Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity. These activities also meet MOC Part II Lifelong Learning and Self-Assessment Module (SAMs CME) requirements. ASCP designates these live activities for a maximum of 1.0 CMLE credit. These activities meet CMP and state re-licensure requirements for laboratory personnel. For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a .m. to 6 p.m. Eastern Time Method of Participation To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line. Funded by an independent educational grant from Pfizer.